Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Pazdur says the time has come for an Oncologic Drugs Advisory Committee meeting devoted to issues surrounding use of progression-free survival endpoints - including clinical relevance.
Advertisement

Related Content

FDA Oncology Panel To Weigh Independent Review Of PFS Event Subset
AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications
AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications
Statistical Significance Does Not Prove Clinical Relevance, FDA Says
Statistical Significance Does Not Prove Clinical Relevance, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS069980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel